Literature DB >> 19364851

Prevalence of fluoroquinolone resistance among tuberculosis patients in Shanghai, China.

Peng Xu1, Xia Li, Ming Zhao, Xiaohong Gui, Kathryn DeRiemer, Sebastien Gagneux, Jian Mei, Qian Gao.   

Abstract

We determined the prevalence of fluoroquinolone resistance among the isolates of Mycobacterium tuberculosis from 605 pulmonary tuberculosis patients in Shanghai, China. Mutations in gyrA were found in 81.5% of phenotypically fluoroquinolone-resistant isolates and were used as a molecular marker of fluoroquinolone resistance. gyrA mutations were detected in 1.9% of strains pan-susceptible to first-line drugs and 25.1% of multidrug-resistant strains. Fluoroquinolone resistance was independently associated with resistance to at least one first-line drug and prior tuberculosis treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19364851      PMCID: PMC2704692          DOI: 10.1128/AAC.00177-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas.

Authors:  J-Y Wang; P-R Hsueh; I-S Jan; L-N Lee; Y-S Liaw; P-C Yang; K-T Luh
Journal:  Thorax       Date:  2006-06-29       Impact factor: 9.139

2.  Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes.

Authors:  G Canetti; W Fox; A Khomenko; H T Mahler; N K Menon; D A Mitchison; N Rist; N A Smelev
Journal:  Bull World Health Organ       Date:  1969       Impact factor: 9.408

3.  Fluoroquinolone susceptibility among Mycobacterium tuberculosis isolates from the United States and Canada.

Authors:  Lorna Bozeman; William Burman; Beverly Metchock; Lauren Welch; Marc Weiner
Journal:  Clin Infect Dis       Date:  2005-01-07       Impact factor: 9.079

4.  Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens.

Authors:  W W Yew; C K Chan; C H Chau; C M Tam; C C Leung; P C Wong; J Lee
Journal:  Chest       Date:  2000-03       Impact factor: 9.410

5.  Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations.

Authors:  H E Takiff; L Salazar; C Guerrero; W Philipp; W M Huang; B Kreiswirth; S T Cole; W R Jacobs; A Telenti
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

Review 6.  Fluoroquinolones, tuberculosis, and resistance.

Authors:  Amy Sarah Ginsburg; Jacques H Grosset; William R Bishai
Journal:  Lancet Infect Dis       Date:  2003-07       Impact factor: 25.071

7.  [Antibiotic susceptibility of Neisseria gonorrhoeae epidemic strains in Changsha].

Authors:  Ming-xiang Zou; Zhong-di Xia; Xiang-hui Liang
Journal:  Hunan Yi Ke Da Xue Xue Bao       Date:  2003-02-28

8.  Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra.

Authors:  T Kocagöz; C J Hackbarth; I Unsal; E Y Rosenberg; H Nikaido; H F Chambers
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

9.  Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients.

Authors:  G J Alangaden; E K Manavathu; S B Vakulenko; N M Zvonok; S A Lerner
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

10.  Transmission of MDR and XDR tuberculosis in Shanghai, China.

Authors:  Ming Zhao; Xia Li; Peng Xu; Xin Shen; Xiaohong Gui; Lili Wang; Kathryn Deriemer; Jian Mei; Qian Gao
Journal:  PLoS One       Date:  2009-02-03       Impact factor: 3.240

View more
  15 in total

1.  Molecular detection of fluoroquinolone-resistance in multi-drug resistant tuberculosis in Cambodia suggests low association with XDR phenotypes.

Authors:  Corinne Surcouf; Seiha Heng; Catherine Pierre-Audigier; Véronique Cadet-Daniel; Amine Namouchi; Alan Murray; Brigitte Gicquel; Bertrand Guillard
Journal:  BMC Infect Dis       Date:  2011-09-28       Impact factor: 3.090

Review 2.  Current prospects for the fluoroquinolones as first-line tuberculosis therapy.

Authors:  Howard Takiff; Elba Guerrero
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

3.  Molecular characterization of multidrug- and extensively drug-resistant Mycobacterium tuberculosis strains in Jiangxi, China.

Authors:  Xiaoliang Yuan; Tiantuo Zhang; Kazuyoshi Kawakami; Jiaxin Zhu; Hongtao Li; Jianping Lei; Shaohua Tu
Journal:  J Clin Microbiol       Date:  2012-05-02       Impact factor: 5.948

4.  Molecular diagnosis of fluoroquinolone resistance in Mycobacterium tuberculosis.

Authors:  Christine Bernard; Nicolas Veziris; Florence Brossier; Wladimir Sougakoff; Vincent Jarlier; Jérôme Robert; Alexandra Aubry
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

5.  Subpopulation analysis of heteroresistance to fluoroquinolone in Mycobacterium tuberculosis isolates from Beijing, China.

Authors:  Xiaobing Zhang; Bing Zhao; Liguo Liu; Yafang Zhu; Yanlin Zhao; Qi Jin
Journal:  J Clin Microbiol       Date:  2012-01-18       Impact factor: 5.948

6.  Prevalence and proliferation of antibiotic resistance genes in the subtropical mangrove wetland ecosystem of South China Sea.

Authors:  Huaxian Zhao; Bing Yan; Xueyan Mo; Pu Li; Baoqin Li; Quanwen Li; Nan Li; Shuming Mo; Qian Ou; Peihong Shen; Bo Wu; Chengjian Jiang
Journal:  Microbiologyopen       Date:  2019-06-28       Impact factor: 3.139

7.  Sequence Analysis of Fluoroquinolone Resistance-Associated Genes gyrA and gyrB in Clinical Mycobacterium tuberculosis Isolates from Patients Suspected of Having Multidrug-Resistant Tuberculosis in New Delhi, India.

Authors:  Ritu Singhal; Paul R Reynolds; Jamie L Marola; L Elaine Epperson; Jyoti Arora; Rohit Sarin; Vithal Prasad Myneedu; Michael Strong; Max Salfinger
Journal:  J Clin Microbiol       Date:  2016-06-22       Impact factor: 5.948

8.  Determination of MICs of levofloxacin for Mycobacterium tuberculosis with gyrA mutations.

Authors:  P Kambli; K Ajbani; C Nikam; A Khillari; A Shetty; Z Udwadia; S B Georghiou; T C Rodwell; A Catanzaro; C Rodrigues
Journal:  Int J Tuberc Lung Dis       Date:  2015-10       Impact factor: 2.373

9.  Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China.

Authors:  Zhijian Zhang; Jie Lu; Yufeng Wang; Yu Pang; Yanlin Zhao
Journal:  Antimicrob Agents Chemother       Date:  2013-10-28       Impact factor: 5.191

10.  Rapid detection of fluoroquinolone-resistant and heteroresistant Mycobacterium tuberculosis by use of sloppy molecular beacons and dual melting-temperature codes in a real-time PCR assay.

Authors:  Soumitesh Chakravorty; Bola Aladegbami; Kimberley Thoms; Jong Seok Lee; Eun Gae Lee; Vignesh Rajan; Eun-Jin Cho; Hyunchul Kim; Hyunkyung Kwak; Natalia Kurepina; Sang-Nae Cho; Barry Kreiswirth; Laura E Via; Clifton E Barry; David Alland
Journal:  J Clin Microbiol       Date:  2010-12-29       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.